On February 12, Shanghai Yizhong and Baheal Pharmaceuticals signed a cooperation agreement in Qingdao. ) to cooperate with the commercialization of Zisheng® to jointly promote the accessibility of domestic innovative tumor drugs and benefit many domestic tumor patients.
It is reported that paclitaxel products, as the cornerstone drugs of anti-tumor chemotherapy, have a wide range of indications, precise curative effects and large clinical needs. The “paclitaxel polymer micelles for injection” Zisheng® independently developed by Shanghai Yizhong is the latest dosage form of 2.2 third-generation paclitaxel approved by the National Medical Products Administration (NMPA) (an innovative dosage form that has not been marketed at home and abroad), and it is also the latest dosage form of the third-generation taxol approved by the National Medical Products Administration (NMPA). It is the first paclitaxel micelle to be approved for marketing, and its Phase III clinical research has been approved as the first batch of projects in the “13th Five-Year Plan” of the national “Major New Drug Creation” science and technology major project. Compared with other paclitaxel dosage forms on the market, paclitaxel micelles have relatively better safety when the clinical dose is greatly increased; the results of clinical trials for non-small cell lung cancer (NSCLC) show that the objective response rate of paclitaxel micelles (ORR) has been significantly improved, and progression-free survival (PFS) has been significantly prolonged. In the first-line treatment of advanced non-small cell lung cancer, both efficacy and safety have shown its unique advantages and advancement. It will become the first-line chemotherapy drug for non-small cell lung cancer. New selection.
At the signing ceremony, Zhou Jinsong, chairman of Shanghai Yizhong, said: “Shanghai Yizhong is committed to developing a new generation of innovative drugs, providing patients with safe, effective and affordable high-quality drugs to meet the urgent treatment needs. Paclitaxel micelles are our The first product on the market, in the commercialization stage, hopes to cooperate with a professional third-party commercialization platform such as Baheal Pharmaceuticals to jointly promote the entry of innovative drug products into the market and benefit more tumor patients.”
Fu Gang, Chairman of Baheal Pharmaceuticals, said: “Baiyang Pharma, as a third-party commercialization platform centered on brand operation, has strict product selection criteria. First, it chooses products that can truly optimize clinical application scenarios, and second, it relies on professional evaluation. Ability to evaluate the technical barriers of products to avoid falling into a low-level duplication dilemma, and thirdly, to do a good job in the allocation of elements through ecological synergy, and select products that can truly complement and synergize with Baheal Resources for commercial operation.”
“Paclitaxel Micellar Zisheng® is the third-generation paclitaxel, which has remarkable curative effect and good safety, and is a revolutionary product. Baheal Pharma will do a good job in the configuration of elements according to the characteristics of its life cycle, and formulate reasonable commercial solutions to help products release value.” Fu Gang further said. (Zhang Yang)Return to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.